GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » Piotroski F-Score

ALMS (Alumis) Piotroski F-Score


View and export this data going back to 2024. Start your Free Trial

What is Alumis Piotroski F-Score?

Alumis does not have enough data to calculate Piotroski F-Score.


Alumis Piotroski F-Score Historical Data

The historical data trend for Alumis's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alumis Piotroski F-Score Chart

Alumis Annual Data
Trend Dec22 Dec23
Piotroski F-Score
N/A N/A

Alumis Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial N/A N/A N/A N/A N/A

Competitive Comparison of Alumis's Piotroski F-Score

For the Biotechnology subindustry, Alumis's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alumis's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alumis's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Alumis's Piotroski F-Score falls into.


Alumis  (NAS:ALMS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Alumis Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Alumis's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Alumis Business Description

Traded in Other Exchanges
N/A
Address
280 East Grand Avenue, South San Francisco, CA, USA, 94080
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.